Sangamo Therapeutics

CA - RichmondBiotechnology1 H-1B visas (FY2023)

Focus: Sangamo Therapeutics is a mid-cap biotech focused on gene therapy and cell therapy using zinc finger nuclease (ZFN) technology and adeno-associated virus (AAV) delivery platforms. The company targets rare and severe diseases across neurology, infectious diseases, and metabolic indications.

Neurology Infectious Diseases Rare Diseases Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1mo ago

Open Jobs

1+1 this month

Stable — net +1 jobs in 30d

1 added, 0 removed. Backfill posture.

Should You Work at Sangamo Therapeutics?

AI assessment

Sangamo is a high-risk, high-reward early-stage gene therapy play suitable for scientists and translational specialists willing to bet on novel modalities, but not for those seeking near-term job security or commercial scale.

Why Work Here

Access to cutting-edge gene therapy platforms (AAV, ZFN) with potential to treat previously intractable diseases like Alzheimer's and Parkinson's

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

30 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Blood sample

Kidney Transplant Rejection

N/A

Clinical Trials (1)

NCT05987527Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

N/A

Help build intelligence for Sangamo Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline spanning 20+ programs across high-need therapeutic areas including neurology, rare metabolic diseases, and HIV

Opportunity to work on Phase 2 programs (CERE-110, CERE-120, SB-509) with clinical validation and upcoming catalysts

Watch Out For

No current commercial revenue generates financial runway risk; pre-commercial biotech operations require tolerance for capital dependency
No Phase 3 programs in pipeline signals extended timeline to first approval (likely 3-5+ years), with no near-term revenue inflection catalysts
Zero active job postings and limited recent H1B sponsorship (1 approval in 2023) suggest minimal active hiring and constrained growth plans

Generated by Claude from Sangamo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

There are no disallowed treatments

HIV-1-infection

N/A

Clinical Trials (1)

NCT04201782Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

N/A

ST-920

Fabry Disease

N/A

Clinical Trials (1)

NCT05039866Long-Term Follow-up of Subjects Who Were Treated With ST-920

N/A

SB-318

Hemophilia B

N/A

Clinical Trials (1)

NCT04628871Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

N/A

BIVV003

Blood and Lymphatic Diseases

N/A

Clinical Trials (1)

NCT05145062Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

N/A

CERE-120: AAV2-NTN

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT00252850Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease

Phase 1

SB-728mR-HSPC Infusion 3 days following busulfan conditioning

HIV

Phase 1

CERE-110: Adeno-Associated Virus Delivery of NGF

Alzheimer's Disease

Phase 1

Clinical Trials (1)

NCT00087789CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Phase 1

ZFN modified T cells

HIV

Phase 1

Clinical Trials (1)

NCT00842634Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

Phase 1

SB-728-T

HIV Infection

Phase 1

Clinical Trials (1)

NCT01044654Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Phase 1

hVEGF-A

Diabetic Neuropathy

Phase 1

Clinical Trials (1)

NCT00110500Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy

Phase 1

SB-FIX

Hemophilia B

Phase 1

Clinical Trials (1)

NCT02695160Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Phase 1

SB-728-T

HIV

Phase 1/2

Clinical Trials (1)

NCT01252641Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

Phase 1/2

SB-318

MPS I

Phase 1/2

Clinical Trials (1)

NCT02702115Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I

Phase 1/2

SB-913

Mucopolysaccharidosis II

Phase 1/2

Clinical Trials (1)

NCT03041324Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

Phase 1/2

SB-728-T

HIV

Phase 1/2

Clinical Trials (1)

NCT01543152Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

Phase 1/2

Plerixafor

Sickle Cell Disease

Phase 1/2

Clinical Trials (1)

NCT03653247A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Phase 1/2

SB-728mR-T

Human Immunodeficiency Virus (HIV)

Phase 1/2

Clinical Trials (1)

NCT02225665Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Phase 1/2

ST-920

Fabry Disease

Phase 1/2

Clinical Trials (1)

NCT04046224Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)